BIIB
Stock Details
BIIB is Biogen Inc.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 202.55$. Average daily volumn in 3 months 1.15M. Market cap 29.87B
Stock symbol : BIIB. Exchange : NasdaqGS. Currency : USD Lastest price : 203.94$. Total volume : 1.19M. Market state PRE Click reload if you want to check the lastest price on market!!!
Biogen Inc. (BIIB)
Last Price
203.94$Change
-1.29Volume
1.19M
| Previous Close | 205.23 |
| Open | 203.58 |
| Day Range | 200.40-206.89 |
| Bid | 201.42 x 900 |
| Ask | 205.20 x 1k |
| Volume | 1.19M |
| Average Volume | 1.15M |
| Market Cap | 29.87B |
| Beta | 0.42 |
| 52 Week Range | 187.16-372.12 |
| Trailing P/E | 20.60 |
| Foward P/E | 12.75 |
| Dividend (Yield %) | N/A |
| Ex-Dividend Date | N/A |
Financial Details
Organization
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXAB... I, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Market Cap:
29.87BRevenue:
10.98BTotal Assets:
23.88BTotal Cash:
2.26B
News about "Biogen Inc."
Creative Financial Designs Inc. ADV Has $38,000 Stock Holdings in Biogen Inc. (NASDAQ:BIIB)
Source from : Defense World - 8 hours ago
Creative Financial Designs Inc. ADV cut its position in shares of Biogen Inc. (NASDAQ:BIIB – Get Rating) by 98.2% during the first quarter, according to the company in its most recent disclosure with ...See details»
AdvisorNet Financial Inc Sells 192 Shares of Biogen Inc. (NASDAQ:BIIB)
Source from : Defense World - 9 hours ago
AdvisorNet Financial Inc cut its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Get Rating) by 23.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange ...See details»
EXCLUSIVE: Has Biotech Bottomed? NYSE Executive Floor Director Says Biogen And These 3 Stocks Look Poised To Outperform
Source from : Business Insider - 1 days ago
Markets continue to trend lower amid rising inflation and Fed uncertainty, but one New York Stock Exchange floor director says the bottom may be in for a couple of beaten-down sectors.See details»
Biogen to reimburse employees who travel 100-plus miles for abortion
Source from : The Business Journals - 1 days ago
In the immediate aftermath of the Supreme Court's decision to overturn nationwide protections for abortion, Cambridge-based Biogen Inc. says it will begin paying for travel for its employees to access ...See details»
Ritholtz Wealth Management Sells 233 Shares of Biogen Inc. (NASDAQ:BIIB)
Source from : ETF Daily News - 1 days ago
Ritholtz Wealth Management lowered its holdings in Biogen Inc. (NASDAQ:BIIB – Get Rating) by 17.9% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The ...See details»
Biogen stops clinical trial tracking Aduhelm
Source from : MarketWatch on MSN.com - 7 days ago
Biogen Inc. said in a statement that it stopped a post-marketing clinical trial testing its Alzheimer's disease therapy Aduhelm, citing a Medicare policy that will limit usage of the drug. The company ...See details»
IBM Retirement Fund Trims Stock Position in Biogen Inc. (NASDAQ:BIIB)
Source from : ETF Daily News - 4 days ago
IBM Retirement Fund lessened its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Get Rating) by 5.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the ...See details»
Five things you need to know, and closing the wealth gap
Source from : The Business Journals - 1 days ago
Good morning, Boston. Here are the five most important things you need to know to start your workday, plus Sally Ride, another venture fund, a new college president, and gathering together to solve ...See details»
Biogen, citing insurance challenges, shutters one of its Aduhelm studies
Source from : BioPharma Dive - 8 days ago
The company says a recent coverage decision by Medicare has forced it to end an observational trial of the Alzheimer's drug after enrolling just 29 participants.See details»
When the Price of Biogen Inc. Common Stock BIIB Talks, People Listen
Source from : news.stocktradersdaily - 7 days ago
Buy BIIB over 195.67 target n/a stop loss @ 195.1. Details; The technical summary data tells us to buy BIIB near 195.67, but there is no curren ...See details»
Biogen pulls plug on Aduhelm real-world study on coverage woes
Source from : Seeking Alpha - 7 days ago
Alzheimer's disease therapy Aduhelm woes seem to continue as the company terminated a study called ICARE AD, which was started to collect real-world data on ...See details»
Biogen Inc. (BIIB) Down 4.8% Since Last Earnings Report: Can It Rebound?
Source from : Nasdaq - 29 days ago
It has been about a month since the last earnings report for Biogen Inc. (BIIB). Shares have lost about 4.8% in that time frame, underperforming the S&P 500. Will the recent negative trend ...See details»
Biogen Secures Tecfidera Patent in EU Until 2028; Generics Not Likely
Source from : Multiple Sclerosis News Today - 8 days ago
Biogen's new patent for its oral MS medication Tecfidera expires in 2028 – so generics likely will not enter the European market until then.See details»
Which Biotech Stock is the Street More Bullish on?
Source from : Nasdaq - 2 days ago
Amid the ongoing market downturn, investors can look for biotech companies with lucrative growth potential that are trading at attractive levels as per Wall Street analysts. Using the Stock Comparison ...See details»